A Phase 2 interventional study of Follitropin Epsilon and Follitropin Alfa in Infertility, sponsored by Glycotope GmbH. Completed at 8 sites in 2 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2021-05-07.
Sponsored by Glycotope GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is the only one in phase 2, and was the 6th registered.
2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 19–37 · Women only · Healthy volunteers
By country, each count listing its studies:
Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 37 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 239 across the 12 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
Glycotope GmbH is the lead sponsor of 9 studies on the registry; none are open to participants now.
Glycotope GmbH has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the current study was the determination of the recommended standard treatment dose of FSH-GEX(TM) in women undergoing intracytoplasmic sperm injection (ICSI) treatment as assessed by follicle growth.
This was a phase II, randomized, assessor-blind, comparator-controlled, multiple dose study in women undergoing ICSI treatment.
The primary objective of the study was the determination of the recommended standard treatment dose of FSH-GEX™ as assessed by follicle growth dynamics in women between 18 and 37 years of age who were undergoing intracytoplasmic sperm injection treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
Drug: Follitropin Epsilon
Follitropin Epsilon 75 IU QD s.c.
Drug: Follitropin Epsilon
Follitropin Epsilon 112.5 IU QD s.c.
Drug: Follitropin Epsilon
Follitropin Epsilon 150 IU QD s.c.
Drug: Follitropin Epsilon
Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
Drug: Follitropin Epsilon
Follitropin alfa 150 IU QD s.c.
Drug: Follitropin Alfa
Also known as: FSH-GEX(TM)
Also known as: Gonal-f(R)
Number of follicles
The number of follicles with a diameter of ≥ 12 mm on the day of human chorionic gonadotropin (hCG) injection after stimulation with follicle stimulating hormone (FSH)
Time frame: day of hCG injection; variable timeframe; up to 18 days for maximum
Follicular response
For each ovary the number of follicles were classified and summarised as follows: mean diameter 8.0 - 9.9 mm, 10.0 - 11.9 mm, 12.0 - 13.9 mm, 14.0 - 15.9 mm, 16.0 - 17.9 mm, 18.0 - 19.9 mm, and \>19.9 mm as determined by transvaginal ultrasonography
Time frame: every second day up to hCG injection; variable timeframe; up to 18 days for maximum
Cumulus-oocyte-complexes
Number of retrieved cumulus-oocyte-complexes
Time frame: at oocyte retrieval; 32 - 36 hours after hCG injection
Oocytes retrieved
Number of oocytes retrieved (metaphase II)
Time frame: at oocyte retrieval; 32 - 36 hours after hCG injection
Two pronuclei oocytes
Number of two pronuclei (2PN) oocytes one day after follicle puncture
Time frame: one day after oocyte retrieval
Biochemical pregnancy rate
Based on positive β-hCG pregnancy test
Time frame: 14 to 20 days after oocyte retrieval
Clinical pregnancy rate
Based on clinical or ultrasound parameters (gestational sac, foetal heart beat
Time frame: approx. 4 to 6 weeks after last FSH dose
Implantation rate
Number of foetal sacs on sonography divided by number of embryos transferred per embryo transfer
Time frame: approx. 4 to 6 weeks after last FSH dose
Estradiol and inhibin B serum levels
Concentration of Estradiol and Inhibin B in Serum after FSH stimulation
Time frame: every second day up to hCG injection; variable timeframe; up to 18 days maximum
Adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability
Incidence of adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability
Time frame: up to 4 to 6 weeks after last FSH dose
Number of doses and total dose of FSH
The total dose is the amount of FSH-GEX(TM) or Gonal-f® administered to each patient during the stimulation period
Time frame: variable timeframe; up to 18 days for maximum
Ongoing pregnancy rate
A pregnancy is considered an ongoing pregnancy if pregnancy can be confirmed for more than 10 weeks after gestation.
Time frame: 10 weeks after gestation
Life birth rate
The live birth rate will be calculated as the total number of live births divided by the number of randomised patients
Time frame: up to nine month after embryo transfer
Plan to share: No
Ran from Jan 2013 to primary completion in Jul 2013, 6 months.
Of 30 phase 2 interventional studies under Infertility, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follicle Stimulating Hormone
Glycotope GmbH